Liquid biopsy technology involves the analysis of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) found in a patient's blood to detect cancer biomarkers. This non-invasive approach allows for the monitoring of disease progression and response to treatment.
Traditional biopsy methods require invasive procedures and can be painful, risky, and logistically challenging for patients. Liquid biopsies offer a safer, more accessible alternative for early detection of cancers and ongoing monitoring of disease status.
Circulating tumor cells are isolated from the bloodstream, often using magnetic beads or microfluidic devices, while cell-free DNA is extracted through techniques such as precipitation or filtration. These samples are then analyzed using various molecular biology methods like PCR, sequencing, or immunoassays to identify specific genetic mutations, epigenetic changes, or other biomarkers associated with cancer.
The manufacturing process involves the development and optimization of sample collection devices, isolation techniques, and analytical methods. This includes the design and production of microfluidic chips, magnetic beads, and reagents used in molecular biology assays.
The build process typically starts with the selection of appropriate biomarkers based on extensive research and clinical validation. Next, the development of specific technologies for sample collection, isolation, and analysis is undertaken. This may involve collaboration between biologists, engineers, and data scientists to ensure accurate and reliable results.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.